Clinical studies show that some individuals feel less hungry just a few days after their initial dose, although the full appetite-suppressing effects may develop gradually over several weeks as the medication builds up in your system
Diabetes Care 36 , 29452951 (2013)
This can make it difficult to get coverage for GLP-1 medications unless they are prescribed for another condition, such as diabetes
Current formulations of GLP-1 analogs rely primarily on subcutaneous injections, which may pose challenges to patient convenience and long-term adherence
Following the publication of the guidelines, criticism and questions have emerged
Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 24 mg for weight management: A randomised, controlled, phase 1b trial